Starting March 1, 2026, new procurement agreements for infliximab prescriptions will be in effect in Sweden, ranked by price. This shift aims to lower healthcare costs although maintaining access to this important medication for patients with conditions like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and severe plaque psoriasis. The change primarily affects how healthcare providers order the drug, with a strong recommendation to prioritize Zessly as the first-line option.
The new pricing structure establishes Zessly as the most affordable option, costing 473.70 Swedish kronor per 100 mg of infliximab. Flixabi’s price remains confidential, while Remicade, the originator brand, is significantly more expensive at 1,549 kronor per 100 mg. Perhaps the most notable change involves Remsima, which previously held the first-line recommendation. From March 1st, all Remsima purchases will be made at its list price, currently around 2,730 kronor per 100 mg, a substantial increase.
What is Infliximab and Why the Change?
Infliximab is a biologic medication used to treat a range of autoimmune conditions. As a tumor necrosis factor (TNF) blocker, it works by suppressing the immune system’s overactive response in these diseases. The availability of biosimilars – medications that are highly similar to the original biologic drug – has created an opportunity to drive down costs. Biosimilars like Zessly, Flixabi, and Remsima have been approved as alternatives to the original Remicade, offering comparable efficacy and safety profiles. The Psoriasis Association provides detailed information about infliximab and its uses.
The shift in procurement agreements is a direct result of these cost differences. By prioritizing the most affordable options, healthcare systems aim to optimize resource allocation and ensure sustainable access to essential medications. The Swedish healthcare system’s decision reflects a broader trend toward utilizing biosimilars to reduce drug expenditures.
Impact on Patients and Healthcare Providers
For patients currently receiving Remsima, this change shouldn’t directly impact their treatment, but it may lead to a discussion with their healthcare provider about the new recommendations. Healthcare professionals are being urged to begin prescribing Zessly as the first-line infliximab product starting March 1st. This transition is intended to be seamless, with the goal of maintaining treatment continuity for patients.
The change primarily affects the ordering process for healthcare providers. They will now be incentivized to select Zessly when prescribing infliximab. While Flixabi remains an option, its price is not publicly disclosed, making it difficult to assess its cost-effectiveness compared to Zessly. Remicade, with its higher price tag, is expected to be reserved for situations where other options are not suitable.
Timeline and Contract Details
The new procurement agreements are effective from March 1, 2026, and can be extended for a maximum period until February 28, 2030. This provides a stable framework for infliximab prescribing over the next several years. The agreements are designed to encourage competition among manufacturers and ensure that patients benefit from the lower prices offered by biosimilars.
The decision to prioritize Zessly is based on its competitive pricing. The availability of multiple infliximab biosimilars – including Zessly, Flixabi, Remsima, and others like Inflectra – has increased choice and driven down costs. Remicade’s official website provides information about the original biologic and its uses.
Understanding Biosimilars
Biosimilars are not identical copies of the original biologic drug, but they are highly similar in terms of their structure and function. They undergo rigorous testing to demonstrate that they are as safe and effective as the original biologic. The European Medicines Agency (EMA) has approved several infliximab biosimilars, including Zessly, ensuring their quality and efficacy. The EMA recently approved Zessly, further solidifying its position in the market.
This change in procurement strategy is a significant step toward making infliximab treatment more affordable and accessible for patients in Sweden. Healthcare providers are encouraged to familiarize themselves with the new guidelines and prioritize Zessly prescriptions starting March 1, 2026. The long-term contracts, extending to February 2030, provide stability and predictability for both patients and healthcare systems.
The next key date to watch is February 28, 2030, when the current procurement agreements will be up for renewal, potentially leading to further adjustments based on market dynamics and the availability of new biosimilars.
Have thoughts on this change? Share your comments below, and please share this article with anyone who might locate it helpful.
